Sector Focus | Core Technology: New class of protein therapeutics
for treating lung diseases
Mission Statement | Company Vision: AATec develops a new class of biotherapeutics for the treatment of inflammatory respiratory diseases. Our mission is to provide broadly active causative treatments that go beyond symptom management.

Products | Services:

• ATL-105, a new recombinant version of alpha-1 antitrypsin for inhalation. It is delivered via a proprietary handheld nebulizer for the treatment of inflammatory and infective lung diseases.

Target Market | Application Area: Lead indication: non-cystic fibrosis bronchiectasis (NCFB), a debilitating chronic respiratory disease with high unmet medical need. Beyond NCFB: COPD, asthma, airway infections, ARDS and bronchiolitis obliterans syndrome (BOS).
Unique Selling Proposition (USP): Broad multimodal activity against key disease drivers of neutrophilic airway inflammation: neutrophil serine proteases, proinflammatory cytokines, bacterial proteases and viral host factors. Inhaled delivery provides high lung drug deposition while overall doses are low and systemic exposure is minimal.